http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
다발성 골수종에서 저용량 thalidomide, cyclophosphamide, dexamethasone (TCD) 요법의 효과
류충헌,정재현,고정해,장제혁,박영진,최규남,박봉수,이상민,주영돈 인제대학교 2008 仁濟醫學 Vol.29 No.-
Background and Objectives : The immunomodulatory drug thalidomide can inhibit angiogenesis and induce apoptosis in experimental models. It can also induce marked and durable response in newly diagnosed myeloma patients. Thalidomide has been used at doses ranging from 200 to 800 mg with significant toxicity. No data are available on the impact of low-dose thalidomide, cyclophosphamide and dexamethasone as initial therapy for myeloma patients. Design and Methods : To address this issue, newly diagnosed myeloma patients were treated with 50 mg/day thalidomide continuously and cyclophosphamide 150 mg/m², days 1-4 and dexamethasone 20 mg/m², days 1-5 and day 15-19, every month. Between October 2005 and October 2006, 14 patients (median age 54.5 years) were treated with low-dose thalidomide, cyclophosphamide and dexamethasone. Results : After a minimum of two cycles of treatment, 5 patients (55.5%) showed a partial remission. After four cycles of treatment, 10 patients (83.3%) showed a partial remission (n=6) and complete remission (n=4). After a median follow-up of 15.4 months, 1 year overall survival rate was 82.0%. Thalidomide was well tolerated without serious toxic effects. Conclusions : The combination of low-dose thalidomide, cyclophosphamide and dexamethasone demonstrates favorable response rate and 1 year overall survival rate in newly diagnosed myeloma. Severe toxicities were not seen with this combination.
각종 간질환에서 B 형 간염 바이러스 DNA polymerase 활성도와 HBeAg의 관계
최상욱 ( Sang Wook Choi ),김부성 ( Boo Sung Kim ),박두호 ( Doo Ho Park ),이창돈 ( Chang Don Lee ),정진우 ( Jin Wu Jeong ),강혜정 ( Hea Jung Kang ),정욱성 ( Wook Sung Jeong ) 대한소화기학회 1988 대한소화기학회지 Vol.20 No.1
N/A DNA-Polymerase and HBeAg appear to be indicaters of relative infectivity of HBsAg-positive serum. The acute disease in the HBeAg-positive patients with acute hepatitis differed significantly from that of HBeAg-negative (HBsAg-positivie) patients. However it did not correlate with the type or severity of liver disease after HBV infection, since HBeAg was present in both chronic benign and chronic active hepatitis B infections. Presence of HBeAg was associated with increase in DNA polymerase activity and in number of circulating Dane particles in previous reports, but it does not correlate with DNA polymerase activity, Dane particles in our studies. To evaluate the activity of HBV DNA in various liver disease, we studed it in 20 patients with CAH, HCC, and 10 patients, who is carrier state with HBeAg, without HBeAg, AVH and CPH respectively. The mean value of HBV DNA polymerase activity is 4092.60+5429.36 cpm in HBe-positive heathy carriers, 203.80+52.80 cpm in HBe-negative healthy carriers, 386.30+471.58 cpm in CPH, 742.05+942. 77 cprn in VAH, 211.95+110.27 cpm in HCC, and 413.50+77.60 cpm in AVH. These results suggest that onging hepatitis B viral replication is more active in HBeAg positive healthy carriers than in carriers without HBeAg, a finding that may help explain the high prevalence of individuals. Thus, DNA polymerase appears to identify the period of peak hepatitis B virus replication, the result of antiviral agents therapy, and test will be useful in evaluating the safety and efficacy of future hepatitis B virus infection.